(Q37976974)

26 August 2017

title

Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension (English)

1 reference

26 August 2017

main subject

arterial hypertension

0 references

author name string

Hirotaka Shibata

series ordinal

1

1 reference

26 August 2017

Hiroshi Itoh

series ordinal

2

1 reference

26 August 2017

publication date

19 January 2012

1 reference

Journal of Clinical Hypertension

26 August 2017

published in

1 reference

26 August 2017

volume

25

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

514-523

1 reference

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Eplerenone in patients with systolic heart failure and mild symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Cardiovascular outcomes in patients with primary aldosteronism after treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Renal damage in primary aldosteronism: results of the PAPY Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Prevalence of resistant hypertension in the United States, 2003-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Resistant hypertension and aldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Serum aldosterone and the incidence of hypertension in nonhypertensive persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

The mineralocorticoid receptor: a journey exploring its diversity and specificity of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

NF-YC functions as a corepressor of agonist-bound mineralocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

The mineralocorticoid receptor and its coregulators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Ubc9 interacts with chicken ovalbumin upstream promoter-transcription factor I and represses receptor-dependent transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Ubc9 and Protein Inhibitor of Activated STAT 1 Activate Chicken Ovalbumin Upstream Promoter-Transcription Factor I-mediated Human CYP11B2 Gene Transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Suppression of TSH in congenital hypothyroidism is significantly related to serum levels and dosage of thyroxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Coactivation of SF-1-mediated transcription of steroidogenic enzymes by Ubc9 and PIAS1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

New aspects of rapid aldosterone signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Position paper: Rapid responses to steroids: current status and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Cell membrane-associated mineralocorticoid receptors? New evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Efficacy of low-dose spironolactone in subjects with resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Prevalence and characteristics of the metabolic syndrome in primary aldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Adipokines and cardiometabolic profile in primary hyperaldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Human adipocytes secrete mineralocorticoid-releasing factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Human adipocytes induce an ERK1/2 MAP kinases-mediated upregulation of steroidogenic acute regulatory protein (StAR) and an angiotensin II-sensitization in human adrenocortical cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Plasma aldosterone is independently associated with the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Association of adrenal steroids with hypertension and the metabolic syndrome in blacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

The incidence and implications of aldosterone breakthrough

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Resistant hypertension and sleep apnea: pathophysiologic insights and strategic management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Are melatonin and its receptor agonist specific antihypertensive modulators of resistant hypertension caused by disrupted circadian rhythm?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

The role of aldosterone in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Mineralocorticoid receptor antagonists and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Management of blood pressure in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Aldosterone-receptor antagonism in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Aldosterone in the pathogenesis of chronic kidney disease and proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Aldosterone blockade in chronic kidney disease: can it improve outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Mineralocorticoid receptor blockade in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Aldosterone blockade in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Cyclin-dependent kinase 5 modulates the transcriptional activity of the mineralocorticoid receptor and regulates expression of brain-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Proteasome-mediated mineralocorticoid receptor degradation attenuates transcriptional response to aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Osmotic stress regulates mineralocorticoid receptor expression in a novel aldosterone-sensitive cortical collecting duct cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Non-classical actions of the mineralocorticoid receptor: misuse of EGF receptors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

EGF receptor as a drug target in arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

The role of protein kinase C activation and the vascular complications of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Activation of protein kinase C isoforms and its impact on diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Targeting the protein kinase C family in the diabetic kidney: lessons from analysis of mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

The effect of ruboxistaurin on nephropathy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

O-GlcNAc modification, insulin signaling and diabetic complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Autosomal Dominant Pseudohypoaldosteronism Type 1: Mechanisms, Evidence for Neonatal Lethality, and Phenotypic Expression in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

7 January 2021

Long-term renal outcomes in patients with primary aldosteronism

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

7 January 2021

The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

7 January 2021

GPR30, mineralocorticoid receptors, and the rapid vascular effects of aldosterone

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

7 January 2021

GPR30 Expression Is Required for the Mineralocorticoid Receptor–Independent Rapid Vascular Effects of Aldosterone

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

7 January 2021

Aldosterone and refractory hypertension: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

7 January 2021

Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

7 January 2021

Mineralocorticoid Receptor Antagonist Reduces Renal Injury in Rodent Models of Types 1 and 2 Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

7 January 2021

Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

7 January 2021

Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

7 January 2021

Modulation of transcription factor function by O-GlcNAc modification

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.245

7 January 2021

Identifiers

DOI

10.1038/AJH.2011.245

1 reference

26 August 2017

1 reference